JY306 universal NK cell injection
2024-SR-1013
Phase 1 mab active
Quick answer
JY306 universal NK cell injection for Relapsed or Refractory Hematological Malignancies is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Relapsed or Refractory Hematological Malignancies
- Phase
- Phase 1
- Modality
- mab
- Status
- active